Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Authors Cardresearch
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Links Registry of Trials

This article is included in 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
Loading references information
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a potential anti-inflammatory role of Fluvoxamine, Fluoxetine, Budesonide and Spirulin Platensis in SARS-CoV-2 infections and observational studies have suggested a reduced complications in patients with COVID-19 disease.
Epistemonikos ID: d5ad52d607dda5d9132c1cd394f63b10b1df1e1a
First added on: Jan 28, 2021